Opus Genetics Inc., a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, has announced a $25 million private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock at $3.39 per share. The financing round is led by Adage Capital Management, with participation from Trails Edge Capital Partners and Marshall Wace. The shares and underlying common stock have not been registered under the Securities Act of 1933 and are subject to restrictions on transfer. Opus Genetics plans to use the proceeds to advance its gene therapy clinical programs and for general corporate purposes. The company expects the offering to close on February 18, 2026, subject to customary conditions, and anticipates the funds will support operations into the first half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9654504-en) on February 13, 2026, and is solely responsible for the information contained therein.